METHODS:
l Reimbursement application pathways for inpatient and outpatient medical devices were evaluated for Austria, Germany and Switzerland by conducting a targeted literature search analysing the reimbursement pathways and requirements reported. Additionally relevant institutional sites were screened for relevant documents (e.g. Hauptverband in Austria, Gemeinsamer Bundesausschuss (G-BA) in Germany, Bundesamt für Gesundheit (BAG) in Switzerland, etc.). The key items being analysed for similarities and differences in each setting were: -Process transparency: How transparent is the process? The categories dedicated to the different countries were high, medium and low. Transparency was measured on the level of reporting of process and reimbursement decisions.
-Clinical evidence: Is clinical evidence required for reimbursement decisions? A rating of "high" and "low" was applied. If the level was "high randomized controlled clinical trials (RCT's) were required and if "low" any kind of evidence including small single-arm evidence might be acceptable.
-Health economics:
Are any health economic data required for reimbursement decisions? If yes the type of health economic data and method of evaluation was described.
-Timing determined: Is there a submission timeline provided under which new reimbursement requests need to be submitted? Yes/No and a description of the timelines applied are provided.
-Length of procedure: What is the average time from reimbursement request submission to the final reimbursement of a medical device?
The average time is indicated according to the findings reporting it.
RESULTS:
-Reimbursement by means of the "Leistungsorientierte Krankenanstaltenfinanzierung -LKF" ("Performance-oriented hospital financing").
-Application for reimbursement: Filing by hospitals (closed electronic system).
-High-level clinical and economic evidence.
-Submission by end of October each year.
-Decision taken by the "Bundesgesundheitskommission" (Federal Healthcare Commission) in June of the following year.
-Basis of decision of the commission: Recommendation of a board of experts and the "LBI for HTA" which strictly apply the EBM and HTA principles (LBI: Ludwig-Boltzmann Gesellschaft).
-In case of a positive decision: Reimbursement of new procedure from the beginning of the following year. -Reimbursement in the outpatient sector is not regulated in detail. Hence, there is no uniform reimbursement catalogue for medical devices, and no standardized, transparent application process.
-Sick-funds negotiate overall contracts and tariffs.
-Individual companies cannot apply directly for inclusion of their products in the tariffs.
-Since there is no official formal procedure for the inclusion of new products into the tariffs, there is also no possibility to appeal a negative decision.
-As a general rule, prices for new products have to be lower than the cheapest product in the respective group of products. The only possibility to achieve a price premium for new, innovative products is to negotiate a new product category.
-Manufacturers or distributors can -but don't have to -present their innovations to the so-called "Fachbeirat", a consulting committee of the "Hauptverband", which assesses performance, quality and efficiency of medical devices.
-The "Fachbeirat" typically invites manufacturers to provide evidence in the form of clinical studies, internal and external experts are also heared.
-The "Fachbeirat" provides recommendations regarding reimbursement to the sick-funds, but does not take any decisions.
-The sick-funds are free to use these recommendations in their direct negotiations with medical device manufacturers or distributors.
-The "Hauptverband" also maintains a department that provides decision support for the sick-funds in the form of EBM expertise and HTAs (mostly done for health interventions and procedures). -The reimbursement fee of a new medical device depends on the available coding, grouping & coverage options.
Germany

CE Mark Inpatient
-For each reimbursement pathway there are specific application procedures available -with a clear process & timing structure.
-There is no need to provide detailed clinical or health economic evidence during the inpatient reimbursement application process. 
Germany -Outpatient
-For the application of a new medical device in the outpatient sector a positive reimbursement decision is mandatory.
-The first strategy should be to apply for inclusion in the EBM (the uniform assessment standard of the physician's fee schedule) and GOÄ (physician's fee schedule for private health insurance provisions) fee schedules; or if applicable for inclusion in the HMV.
-The 'IGeL inclusion' (out-off pocket payment) should be seen as fallback strategy.
-It is mandatory to provide specific clinical and health economic evidence during the application process.
l 'Selective Contracting' can be set up by all SHI'S (mandatory integral part), all health care providers, all management organizations in addition to SHI regular care (collective contracts). The choice of the contractual basis depends mainly on the content design of the selective contract for the special forms of health care; it is mandatory to provide specific clinical and health economic evidence during the application for an inclusion in the selected contract to the advisory board.
l To be applicable for the 'Experimental Coverage' program (reimbursement while additional evidence is generated in clinical trials) a new medical device needs to show a strong "potential"; this usually means it needs to be innovative in a patient population with a high unmet medical need in order to be eligible for reimbursement under the 'Experimental Coverage' program.
Switzerland Figure 2: Reimbursement pathways for medical devices in Switzerland
BAG = Federal Office of Public Health (FOPH/BAG)
l Swiss hospitals and physicians enjoy the ‚principle of trust', which means that they have to chose treatments that are effective, appropriate and economically viable (called the ‚WZW criteria').
l Medical devices that are new, modified or controversial to existing comparator therapies may need to go through an appraisal process and explicitly listed in Appendix 1 of the KLV.
l It is advisable to send a report form to the Federal Office of Public Health (BAG) if introducing a novel, modified or controversial medical service or device.
l The BAG will review the report form and advise the manufacturer if the product needs to go through the appraisal process to be reimbursed.
l Tariffs for the overall medical service provided are negotiated between health providers, health insurance companies and cantons and integrated into the SwissDRG or TARMED systems.
Main findings
Inpatient Setting l In the inpatient setting, the evidence requirements for clinical data are different between the analysed countries:
-The lowest clinical evidence requirements are seen in Germany, while the highest are given in Switzerland (in the scenario of a full HTA submission).
-In terms of health economics the requirements are medium to low. A medium rating was given for Austria and Switzerland (in some scenarios) as a health economic analysis is required (e.g. cost comparison), and a low rating was applied to Germany as limited economic information (cost assessment/comparison) needs to be submitted.
-The length of the application process is well defined in Austria and Germany and vague in Switzerland. In the outpatient setting the requirements for clinical and health economic data are significantly increasing in all countries analyzed.
-Clinical requirements are getting close to pharmaceutical methods whereas health economic evidence is requested in all DACH countries.
-The length of the reimbursement process is not clearly defined in all three countries. 
CONCLUSION:
l Despite varying reimbursement processes within the DACH region, there are some important similarities between the evidence requirements; especially if separating the reimbursement processes by the sectors (inpatient/outpatient).
l These similarities may help manufacturers to guide market access and reimbursement strategy decisions in the DACH countries more efficiently in order to drive successful submissions and applications of innovative medical devices.
